acetylated peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
| Property | Value | Notes |
|---|---|---|
| 主要靶细胞 | T细胞、树突状细胞 | 也影响NK细胞 |
| 信号通路 | TLR/MyD88/NF-κB | 部分实验模型 |
| 细胞因子偏向 | Th1型 | 增加IL-2、IFN-γ |
| 给药途径 | 皮下注射 | 临床常用 |
| 半衰期 | 约2小时 | 血浆中较短 |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Provided the monosaccharide amino acid building block is stable to peptide coupling conditions, amine deprotection conditions and resin cleavage. Linear assembly remains a popular strategy for the synthesis of glycopeptides with many examples in the literature. In the convergent assembly strategy a peptide chain and glycan residue are first synthesis separately. Then the glycan is glycosylated onto a specific residue of the peptide chain. This approach is not as popular as the linear strategy due to the poor reaction yields in the glycosylation step. Another strategy to produce glycopeptide libraries is using Glyco-SPOT synthesis technique. The technique extends the existing method of SPOT synthesis. In this method, libraries of glycopeptides are produced on a cellulose surface (e.g. filter paper) which acts as the solid phase. The glycopeptides are produced by spotting FMOC protected amino acids allowing the synthesis to be performed at microgram (nanomole) scale using very small amounts of glycoamino acids. The scale of this technique can be an advantage for creating libraries for screening by using less amounts of glycoamino acids per peptide. However to produce larger quantities of glycopeptides traditional resin-based solid phase techniques would be better.
In 2001, various tyrannosaurid teeth and a metatarsal unearthed in a quarry near Zhucheng, China, were assigned by Chinese paleontologist Hu Chengzhi to the newly erected species Tyrannosaurus zhuchengensis. However, in a nearby site, a right maxilla and left jawbone were assigned to the newly erected tyrannosaurid genus Zhuchengtyrannus in 2011. It is possible that T. zhuchengensis is synonymous with Zhuchengtyrannus. In any case, T. zhuchengensis is considered to be a nomen dubium as the holotype lacks diagnostic features below the level Tyrannosaurinae. In 2006, a fragmentary tyrannosaurid lacrimal (CM 9401) from the Judith River Formation of Fergus County, Montana, was described as ?Tyrannosaurus sp. This isolated right lacrimal was originally collected alongside the holotype specimen of Deinosuchus rugosus, a giant crocodilian, and remained undescribed until its re-identification as belonging to a tyrannosaurid theropod in the 1980s by paleontologist Dale Russell. The lacrimal closely resembles those of Tyrannosaurus rex in both size and morphology. Notably, it lacks the "lacrimal horn" typically present in earlier tyrannosaurids like Albertosaurus and Gorgosaurus, instead exhibiting a distinct rugosity along the dorsal surface—consistent with T. rex and its Asian relative Tarbosaurus. The specimen's considerable size places it within the range of known T. rex individuals, suggesting the presence of large tyrannosaurids during the Campanian stage (~75 million years ago), a temporal range earlier than the established Maastrichtian age (~68–66 Ma) for Tyrannosaurus rex.
It is a metabolite in the glutathione cycle that is converted to glutamate by 5-oxoprolinase. Pyroglutamate is found in many proteins including bacteriorhodopsin. N-terminal glutamic acid and glutamine residues can spontaneously cyclize to become pyroglutamate, or enzymatically converted by glutaminyl cyclases. This is one of several forms of blocked N-termini which present a problem for N-terminal sequencing using Edman chemistry, which requires a free primary amino group not present in pyroglutamic acid. The enzyme pyroglutamate aminopeptidase can restore a free N-terminus by cleaving off the pyroglutamate residue. Pyroglutamic acid exists as two distinct enantiomers:
Sources: en.wikipedia.org
In the context of nutrition, a mineral is a chemical element. Some "minerals" are essential for life, but most are not. Minerals are one of the four groups of essential nutrients; the others are vitamins, essential fatty acids, and essential amino acids. The five major minerals in the human body are calcium, phosphorus, potassium, sodium, and magnesium. The remaining minerals are called "trace elements". The generally accepted trace elements are iron, chlorine, cobalt, copper, zinc, manganese, molybdenum, iodine, selenium, and bromine; there is some evidence that there may be more. The four organogenic elements, namely carbon, hydrogen, oxygen, and nitrogen (CHON), that comprise roughly 96% of the human body by weight, are usually not considered as minerals (nutrient). In fact, in nutrition, the term "mineral" refers more generally to all the other functional and structural elements found in living organisms. Plants obtain minerals from soil. Animals ingest plants, thus moving minerals up the food chain. Larger organisms may also consume soil (geophagia) or use mineral resources such as salt licks to obtain minerals. Finally, although mineral and elements are in many ways synonymous, minerals are only bioavailable to the extent that they can be absorbed. To be absorbed, minerals either must be soluble or readily extractable by the consuming organism. For example, molybdenum is an essential mineral, but metallic molybdenum has no nutritional benefit. Many molybdates are sources of molybdenum.
=== Nicaragua === The Castillo Administration refused to recognize the results of the 2021 Nicaraguan general election, saying it did not meet the minimum criteria for free elections. Free Peru's leader Vladimir Cerrón blamed Foreign Minister Óscar Maúrtua for the refusal to recognize Nicaragua's election. Cerrón released a statement saying "Regrettable position adopted by the Ministry of Foreign Affairs - Foreign Ministry of Peru, regarding the elections in Nicaragua, the same position adopted by the reactionary forces to ignore the electoral victory of Pedro Castillo."
C-4 or Composition C-4 is a common variety of the plastic explosive family known as Composition C, which uses RDX as its explosive agent. C-4 is composed of explosives, plastic binder, plasticizer to make it malleable, and usually a marker or odorizing taggant chemical. C-4 has a texture similar to modelling clay and can be molded into any desired shape. C-4 is relatively insensitive and can be detonated only by the shock wave from a detonator or blasting cap. A similar British plastic explosive, also based on RDX but with a plasticizer different from that used in Composition C-4, is known as PE-4 (Plastic Explosive No. 4).
Cantrell explained the reunion saying, We want to celebrate what we did and the memory of our friend. We have played with some [singers] who can actually bring it and add their own thing to it without being a Layne clone. We're not interested in stepping on [Staley's] rich legacy. It's a tough thing to go through. Do you take the Led Zeppelin approach and never play again, because the guy was that important? That's the approach we've taken for a lot of years. Or, do you give it a shot, try something? We're willing to take a chance on it. It's completely a reunion because the three of us who're left are back together. But it's not about separating and forgetting—it's about remembering and moving on. Before the tour, Kinney mentioned in an interview that he would be interested in writing new material, but not as Alice in Chains. During the VH1 Rock Honors concert honoring Heart on May 12, 2007, Alice in Chains performed Heart's "Barracuda" fronted by country singer Gretchen Wilson. Heart's guitarist Nancy Wilson also joined them onstage. Alice in Chains joined Velvet Revolver for a run of U.S. and Canadian gigs from August through October 2007. During that tour, the band also performed four special acoustic-only shows, named as "The Acoustic Hour". The acoustic performance at The Rave/Eagles Club in Milwaukee, Wisconsin on August 31, 2007, was recorded for an upcoming live album.
Sources: en.wikipedia.org
它促进未成熟T细胞分化并增强成熟T细胞的增殖与细胞因子分泌。这些作用有助于放大抗原特异性免疫应答。
目前认为它可能通过Toll样受体等模式识别受体传递信号，但精确的受体身份和结合机制尚未完全阐明。
不同试验在患者选择、给药方案、联合治疗和终点定义上差异很大。这些异质性使得跨研究比较困难，结论难以统一。
Its sequence corresponds to the amino-terminal portion of prothymosin alpha, a larger protein present in many cell types. The isolated 28-residue peptide is a fragment of that protein rather than a separately encoded molecule, and laboratory material is produced by synthesis.